Last reviewed · How we verify
NCT06745414
Clinical Performance of QIAstat-Dx® Gastrointestinal Panel 2
trial in Gastrointestinal Infection in 2,000 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | QIAGEN Gaithersburg, Inc |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 14 September 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Gastrointestinal Infection — all drugs for Gastrointestinal Infection →
Sponsor
QIAGEN Gaithersburg, Inc — full company profile →
Who can join
Eligibility, any sex, with Gastrointestinal Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Performance evaluation of QIAstat-Dx® GI2 Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx® GI2 Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06745414
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Infection
Currently open trials in the same condition.
- NCT04826991 — Wells and Enteric Disease Transmission · NA · active not recruiting
Other QIAGEN Gaithersburg, Inc trials
Trials by the same sponsor.
- NCT06360757 — Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19) · terminated
- NCT06645236 — DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · recruiting
- NCT05305534 — QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study · completed
- NCT05733559 — QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study · completed
- NCT06681025 — Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06745414 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by QIAGEN Gaithersburg, Inc
- Last refreshed: 17 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06745414.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing